ArticleFrontiers in endocrinology2024
Causal relationship between 412 gut microbiota, 1,400 blood metabolites, and diabetic nephropathy: a randomized Mendelian study.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Lactoferrin alleviates non-alcoholic steatohepatitis via remodeling gut microbiota to regulate serotonin-related pathways.Journal of advanced research · 2026Article
- Linkage of gut microbiota dysbiosis to chronic kidney disease in patients with graded proteinuria levels.Microbiology spectrum · 2026Article
- ILC imbalance - a new piece in the gut-kidney axis puzzle.Frontiers in immunology · 2026Review
- Gut Microbiota, Lipidome, and Metabolites Mediate Immune Dysregulation in Diabetic Microvascular Disease: A Two-sample Mendelian Randomization and Mediation Analysis.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Gut microbiome dysregulation is associated with segmental glomerulosclerosis in IgA nephropathy: insights from Oxford classification-based microbiome profiling.Frontiers in cellular and infection microbiology · 2026Article
- Dynamics of Urine Metabolomics and Tubular Inflammatory Cytokines in Type 1 Diabetes Across Disease Durations.Metabolites · 2025Article
- Connection between circulating inflammatory cytokines and non-small cell lung cancer: integrated Mendelian randomization and gene function analysis.Discover oncology · 2025Article
- Gut microbiota dysbiosis in diabetic nephropathy: mechanisms and therapeutic targeting via the gut-kidney axis.Frontiers in endocrinology · 2025Review
- Altered acetate metabolism and signaling in IgA nephropathy: an integrated gut microbiome and glomerular spatial transcriptome analysis.Frontiers in immunology · 2025Article
- Gut microbiota therapy for chronic kidney disease.Frontiers in immunology · 2025Review
- Gut microbiota-derived short-chain fatty acids mediate the antifibrotic effects of traditional Chinese medicine in diabetic nephropathy.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to investigate the causal relationship between microbiota, diabetic nephropathy, and blood metabolites through a randomized Mendelian study. Methods: In this study, we used 412 microbiota as exposures, 1,400 blood metabolites as intermediaries, and diabetic nephropathy as the outcome. We conducted a two-way Mendelian randomization (MR) analysis to explore the causal relationship between microbiota and diabetic nephropathy, followed by mediation analyses and two-step MR to identify potential blood metabolites. Results: There is a causal relationship between microbiota and diabetic nephropathy. Specific bacteria and metabolites, such as Conclusions: For the first time, MR analysis provides supportive evidence for a bidirectional causal relationship between microbiota and diabetic nephropathy and identifies specific genes associated with the disease. The results suggest that probiotic therapy may play a significant role in preventing diabetic nephropathy and improving the quality of life and survival rates of affected patients. Furthermore, this study provides additional evidence of a causal relationship between specific microbiota, diabetic nephropathy, and blood metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.